Buckingham Strategic Partners Amgen Inc Transaction History

Buckingham Strategic Partners

$4.37 Billion
Q3 2024

A detailed history of Buckingham Strategic Partners transactions in Amgen Inc stock. As of the latest transaction made, Buckingham Strategic Partners holds 6,234 shares of AMGN stock, worth $1.64 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

6,234

Previous 6,052 3.01%

Holding current value

$1.64 Million

Previous $1.89 Million 6.24%

% of portfolio

0.05%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$309.38 - $337.38 $56,307 - $61,403	182 Added 3.01%	6,234 $2.01 Million
Q2 2024 Aug 13, 2024	SELL	$262.75 - $319.31 $28,639 - $34,804	-109 Reduced 1.77%	6,052 $1.89 Million
Q1 2024 May 15, 2024	BUY	$268.87 - $324.56 $1.15 Million - $1.38 Million	4,267 Added 225.29%	6,161 $1.75 Million
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $1.06 Million - $1.2 Million	-4,147 Reduced 68.65%	1,894 $545,000
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $378,701 - $470,168	1,732 Added 40.19%	6,041 $1.62 Million
Q2 2023 Aug 14, 2023	SELL	$214.27 - $253.37 $51,210 - $60,555	-239 Reduced 5.26%	4,309 $956,000
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $97,315 - $118,611	-431 Reduced 8.66%	4,548 $1.1 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $367,822 - $467,362	-1,606 Reduced 24.39%	4,979 $1.31 Million
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $288,431 - $325,297	1,285 Added 24.25%	6,585 $1.48 Million
Q2 2022 Aug 12, 2022	SELL	$230.71 - $256.74 $22,840 - $25,417	-99 Reduced 1.83%	5,300 $1.29 Million
Q1 2022 May 10, 2022	BUY	$219.27 - $242.57 $1.18 Million - $1.31 Million	5,399 New	5,399 $1.3 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Buckingham Strategic Partners, based on Form 13F filings with the SEC.

News

Stay updated on Buckingham Strategic Partners with notifications on news.

Account

Buckingham Strategic Partners Amgen Inc Transaction History